Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk's New Obesity Pill Beats Wegovy In Early Trial
Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid competition from Mounjaro maker Eli Lilly, pharma titans like Pfizer and biotech upstarts.
Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids
A late-stage clinical trial showed drug helped children aged 6-11 reduce their BMI.
Weight loss jabs of six-year-olds? Here's the latest clinical findings
A recent study has found that liraglutide, a drug approved for obesity treatment in adults and teens, is safe and effective for children as young as six when combined with diet and exercise. The research, presented at a medical conference and published in the New England Journal of Medicine, showed that liraglutide reduced body mass and slowed weight gain in children aged 6 to 11.
2 Biotech Stocks To Watch In September 2024
Here are biotech stocks to check out this month.
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial
Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects, the company said on Wednesday.
Novo's older obesity drug is safe and effective for children, study finds
Novo Nordisk's older weight-loss drug Saxenda helped children between the ages of 6 and under 12 reduce their body mass index by 7.4% in a 56-week trial, according to results presented at a medical meeting on Wednesday.
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Ozempic shortages in EU will not affect all member states - Novo Nordisk
Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of 2024 because of strong demand will not affect all member states, the Danish drugmaker Novo Nordisk said.
Weight-loss drugs could reduce COVID-related deaths: Study
A new study found that weekly injections of 2.4 mg of semaglutide could lower the risk of deaths related to COVID-19, marking another potential benefit of these blockbuster drugs.
Novo Nordisk's Ozempic shortage expected to continue into Q4
Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
Eli Lilly and Novo Nordisk compete in a handful of different markets. Novo Nordisk is scaling up its output and upgrading its medicines a bit more slowly.
